Severity
Moderate
FDA Drug recall · Reported December 17, 2014
Lack of Assurance of Sterility: Glass vials may have finish fractures and glass particles.
Fresenius Kabi USA, LLC recalled ONDANSETRON INJECTION, USP, 4 mg/ 2 mL (2 mg/mL), For IM or IV Use, Single Dose 2 mL Via… - a moderate-severity action.
ONDANSETRON INJECTION, USP, 4 mg/ 2 mL (2 mg/mL), For IM or IV Use, Single Dose 2 mL Via… was recalled by Fresenius Kabi USA, LLC in December 17, 2014. Reason: Lack of Assurance of Sterility: Glass vials may have finish fractures and glass particles.. Check the official notice for the remedy. Verify recall #D-0296-2015 with the FDA Drug before acting.
The recall
Fresenius Kabi USA, LLC issued this moderate-severity FDA Drug recall-Lack of Assurance of Sterility: Glass vials may have finish fractures and glass particles..
Sourced from official FDA Drug enforcement records. Verify recall #D-0296-2015 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0296-2015) was formally reported on December 17, 2014, with the manufacturer initiating the action on September 27, 2012. It is classified under Moderate severity (Class II), with a current status of Terminated. Fresenius Kabi USA, LLC is listed as the recalling firm, operating out of Lake Zurich, IL. Federal records list the affected scope as 184,550 Vials.
The documented reason for this recall is: Lack of Assurance of Sterility: Glass vials may have finish fractures and glass particles. Distribution data in the federal record shows the product reached: U.S. Nationwide Including Puerto Rico. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
184,550 Vials
Related Recalls
6
5 from same agency
ONDANSETRON INJECTION, USP, 4 mg/ 2 mL (2 mg/mL), For IM or IV Use, Single Dose 2 mL Vials, Rx only. APP Pharmaceuticals, LLC, Schaumburg, IL 60173. NDC: 63323-373-02
Lack of Assurance of Sterility: Glass vials may have finish fractures and glass particles.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0296-2015 |
| Date reported | December 17, 2014 |
| Date initiated | September 27, 2012 |
| Recalling firm | Fresenius Kabi USA, LLC |
| Firm location | Lake Zurich, IL |
| Affected scope | 184,550 Vials |
| Distribution | U.S. Nationwide Including Puerto Rico |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported December 17, 2014. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.